Rxo (RXO) Change in Accured Expenses (2022 - 2026)

Rxo (RXO) has 5 years of Change in Accured Expenses data on file, last reported at -$36.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 140.0% year-over-year to -$36.0 million; the trailing twelve-month figure through Mar 2026 stood at -$19.0 million (down 123.46% YoY), and the FY2025 full-year result was $2.0 million, down 98.29% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$36.0 million, down from $75.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $102.0 million in Q4 2024 and bottomed at -$60.0 million in Q2 2023.
• The 5-year median for Change in Accured Expenses is $1.0 million (2022), against an average of $2.6 million.
• The widest annual swing landed in 2023, when Change in Accured Expenses plunged 957.14%; it then surged 2000.0% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$17.0 million in 2022, then increased by 29.41% to -$12.0 million in 2023, then surged by 950.0% to $102.0 million in 2024, then slipped by 26.47% to $75.0 million in 2025, then tumbled by 148.0% to -$36.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$36.0 million (Q1 2026), $75.0 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.

Peer Comparison